Almost eight years after spinning out AstraZeneca’s antibiotics pipeline, Entasis Therapeutics has landed its first approval.
All 12 members of the FDA’s Antimicrobial Drugs Advisory Committee unanimously voted Monday afternoon in favor of an antibiotic candidate from Entasis Therapeutics, saying that it has a favorable benefit-risk profile for treating patients with two hospital-related bacterial pneumonias.
All 12 members of the FDA’s Antimicrobial Drugs Advisory Committee unanimously voted Monday afternoon in favor of an antibiotic candidate from Entasis Therapeutics, saying that it has a favorable benefit-risk profile for treating patients with two hospital-related bacterial pneumonias.
WALTHAM, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the presentation of additional safety and efficacy data from the Company’s pivotal Phase 3 ATTACK trial. The study results will be presented at IDWeek 2022, the annual meeting of the Infectious Disease Society of America held October 19-23, 2022 in Washington, D.C.
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc., a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, and wholly owned subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that six abstracts highlighting sulbactam-durlobactam (SUL-DUR) have been selected for presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C.
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties, today announced the successful completion of its acquisition of Entasis Therapeutics Holdings Inc. (“Entasis”), an advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products.
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) (“Entasis”) at a price of $2.20 per share, net to the seller in cash, without interest and less required withholding taxes, expired at 5:00 p.m. New York City time on Thursday, July 7, 2022.
WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel...
Innoviva (NASDAQ:INVA) and Entasis Therapeutics Holdings (NASDAQ:ETTX) has entered into a definitive merger agreement under which Innoviva is to acquire all of the outstanding shares of Entasis at a price of $2.2/share in cash.
Highlights of landmark Phase 3 ATTACK trial for sulbactam-durlobactam (SUL-DUR) presented at ECCMID 2022 annual conferenceSUL-DUR NDA submission on track for mid-2022Zoliflodacin Phase 3 trial...